Economic evaluations of Haemophilus influenzae type b vaccine: systematic review of the literature

References

• Makela PH, Takala AK, Peltola H, Eskola J. Epidemiology of invasive Haemophilus influenzae type b disease. J. Infect. Dis.165(Suppl. 1), S2–S6 (1992).
   PubMed Web of Science ®Google Scholar
• Bennett JV, Platonov AE, Slack MPE et al.Haemophilus influenzae type b (Hib) meningitis in the pre-vaccine era: a global review of incidence, age distributions, and case–fatality rates. WHO, Geneva, Switzerland (2002).
   Google Scholar
• Watt JP, Wolfson LJ, O’Brien KL et al. The global burden of disease due to Haemophilus influenzae, type b in children less than 5 years of age. Lancet (2009) (In Press).
   Google Scholar
• Jones G, Steketee RW, Black RE, Bhutta ZA, Morris SS. How many child deaths can we prevent this year? Lancet362(9377), 65–71 (2003).
   PubMed Web of Science ®Google Scholar
• Bryce J, Daelmans B, Dwivedi A et al. Countdown to 2015 for maternal, newborn, and child survival: the 2008 report on tracking coverage of interventions. Lancet371(9620), 1247–1258 (2008).
   PubMed Web of Science ®Google Scholar
• Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology113(2), 163–174 (2004).
   PubMed Web of Science ®Google Scholar
• Rossi IA, Zuber PL, Dumolard L, Walker DG, Watt J. Introduction of Hib vaccine into national immunization programmes: a descriptive analysis of global trends. Vaccine25(41), 7075–7080 (2007).
   PubMed Web of Science ®Google Scholar
• Wenger JD, DiFabio J, Landaverde JM, Levine OS, Gaafar T. Introduction of Hib conjugate vaccines in the non-industrialized world: experience in four ‘newly adopting’ countries. Vaccine18(7–8), 736–742 (1999).
   PubMed Web of Science ®Google Scholar
• WHO. Progress introducing Haemophilus influenzae type b vaccine in low-income countries, 2004–2008. Wkly Epidemiol. Rec.7(83), 61–68 (2008).
   Google Scholar
• Centre for Reviews and Dissemination. Systematic Reviews: CRD’s Guidance for Undertaking Reviews in Health Care. CRD, University of York, York, UK (2009).
   Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes (3rd Edition). Oxford University Press, Oxford, UK (2005).
   Google Scholar
• Initiative for Vaccine Research. WHO Guide for Standardization of Economic Evaluations of Immunization Programmes. WHO, Geneva, Switzerland (2008).
   Google Scholar
• Beutels P, Edmunds WJ, Antonanzas F et al. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics20(1), 1–7 (2002).
   PubMed Web of Science ®Google Scholar
• Guzmán ANRF, Consuelo DV. The cost–effectiveness of Haemophilus influenzae type b vaccine for children under 2 years of age in Colombia. Rev. Panam. Salud Publica20(4), 248–255 (2006).
   PubMedGoogle Scholar
• de Campora E, Pizzuti R. Use of the economic evaluation in the comparison of different vaccination programs against Haemophilus influenzae type b disease. Ann. Ig.7(5), 329–338 (1995).
   PubMedGoogle Scholar
• Martens LL, ten Velden GH, Bol P. Costs and benefits of vaccination against Haemophilus influenzae type b. Ned. Tijdschr. Geneeskd135(1), 16–20 (1991).
   PubMedGoogle Scholar
• Zhou F, Santoli J, Messonnier ML et al. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001. Arch. Pediatr. Adolesc. Med.159(12), 1136–1144 (2005).
   PubMedGoogle Scholar
• Fagnani F, Le Fur C, Durand I, Gibergy M. Economic evaluation of a combined DTPa, hepatitis B, polio, Hib vaccine. Potential impact of the introduction of Infanrix-Hexa in the French childhood immunisation schedule. Eur. J. Health Econ.5(2), 143–149 (2004).
   PubMedGoogle Scholar
• Fendrick AM, Lee JH, LaBarge C, Glick HA. Clinical and economic impact of a combination Haemophilus influenzae and Hepatitis B vaccine: estimating cost–effectiveness using decision analysis. Arch. Pediatr. Adolesc. Med.153(2), 126–136 (1999).
   PubMedGoogle Scholar
• Clements DA. Cost of treatment and prevention of Haemophilus influenzae type b disease. An international perspective. Pharmacoeconomics6(5), 442–452 (1994).
   PubMed Web of Science ®Google Scholar
• Levine OS, Ortiz E, Contreras R et al. Cost–benefit analysis for the use of Haemophilus influenzae type b conjugate vaccine in Santiago, Chile. Am. J. Epidemiol.137(11), 1221–1228 (1993).
   PubMed Web of Science ®Google Scholar
• Midani S, Ayoub EM, Rathore MH. Cost–effectiveness of Haemophilus influenzae type b conjugate vaccine program in Florida. J. Fla. Med. Assoc.82(6), 401–402 (1995).
   PubMedGoogle Scholar
• Asensi F, Otero MC, Perez-Tamarit D et al. Economic aspects of a general vaccination against invasive disease caused by Haemophilus influenzae type b (Hib) via the experience of the Children’s Hospital La Fe, Valencia, Spain. Vaccine13(16), 1563–1566 (1995).
   PubMed Web of Science ®Google Scholar
• Hussain IHMI, Syed A, Sofiah A et al. Cost–benefit analysis of Haemophilus influenzae vaccination programme in Malaysia. Buletin Kesihatan Masyarakat5, 79–89 (1999).
   Google Scholar
• Jimenez FJ, Guallar-Castillon P, Rubio Terres C, Guallar E. Cost–benefit analysis of Haemophilus influenzae type b vaccination in children in Spain. Pharmacoeconomics15(1), 75–83 (1999).
   PubMed Web of Science ®Google Scholar
• Brinsmead R, Hill S, Walker D. Are economic evaluations of vaccines useful to decision-makers? Case study of Haemophilus influenzae type b vaccines. Pediatr. Infect. Dis. J.23(1), 32–37 (2004).
   PubMed Web of Science ®Google Scholar
• Cochi SL, Broome CV, Hightower AW. Immunization of US children with Haemophilus influenzae type b polysaccharide vaccine. A cost–effectiveness model of strategy assessment. JAMA253(4), 521–529 (1985).
   PubMed Web of Science ®Google Scholar
• Hay JW, Daum RS. Cost–benefit analysis of two strategies for prevention of Haemophilus influenzae type b infection. Pediatrics80(3), 319–329 (1987).
   PubMed Web of Science ®Google Scholar
• Ginsberg GM, Kassis I, Dagan R. Cost–benefit analysis of Haemophilus influenzae type b vaccination programme in Israel. J. Epidemiol. Community Health47(6), 485–490 (1993).
   PubMed Web of Science ®Google Scholar
• Zhou F, Bisgard KM, Yusuf HR et al. Impact of universal Haemophilus influenzae type b vaccination starting at 2 months of age in the United States: an economic analysis. Pediatrics110(4), 653–661 (2002).
   PubMed Web of Science ®Google Scholar
• Hussey GD, Lasser ML, Reekie WD. The costs and benefits of a vaccination programme for Haemophilus influenzae type B disease. S. Afr. Med. J.85(1), 20–25 (1995).
   PubMed Web of Science ®Google Scholar
• Duke T. Haemophilus influenzae type b meningitis: how much better is prevention than cure? PNG Med. J.45(3–4), 213–218 (2002).
   PubMedGoogle Scholar
• Limcangco MR, Armour CL, Salole EG, Taylor SJ. Cost–benefit analysis of a Haemophilus influenzae type b meningitis prevention programme in The Philippines. Pharmacoeconomics19(4), 391–400 (2001).
   PubMed Web of Science ®Google Scholar
• Akumu AO, English M, Scott JA, Griffiths UK. Economic evaluation of delivering Haemophilus influenzae type b vaccine in routine immunization services in Kenya. Bull. World Health Organ.85(7), 511–518 (2007).
   PubMed Web of Science ®Google Scholar
• Munson RS Jr, Kabeer MH, Lenoir AA, Granoff DM. Epidemiology and prospects for prevention of disease due to Haemophilus influenzae in developing countries. Rev. Infect. Dis.11(Suppl. 3), S588–S597 (1989).
   PubMedGoogle Scholar
• Mulholland K, Levine O, Nohynek H, Greenwood BM. Evaluation of vaccines for the prevention of pneumonia in children in developing countries. Epidemiol. Rev.21(1), 43–55 (1999).
   PubMed Web of Science ®Google Scholar
• Gessner BD. Haemophilus influenzae type b vaccine impact in resource-poor settings in Asia and Africa. Expert Rev. Vaccines8(1), 91–102 (2009).
   PubMed Web of Science ®Google Scholar
• Shin S, Shin YJ, Ki M. Cost–benefit analysis of Haemophilus influenzae type b immunization in Korea. J. Korean Med. Sci.23(2), 176–184 (2008).
   PubMed Web of Science ®Google Scholar
• Broughton EI. Economic evaluation of Haemophilus influenzae type b vaccination in Indonesia: a cost–effectiveness analysis. J. Public Health (Oxf.)29(4), 441–448 (2007).
   PubMed Web of Science ®Google Scholar
• Gessner BD, Sedyaningsih ER, Griffiths UK et al. Vaccine-preventable Haemophilus influenza type b disease burden and cost–effectiveness of infant vaccination in Indonesia. Pediatr. Infect. Dis. J.27(5), 438–443 (2008).
   PubMed Web of Science ®Google Scholar
• Platonov AE, Griffiths UK, Voeykova MV et al. Economic evaluation of Haemophilus influenzae type b vaccination in Moscow, Russian Federation. Vaccine24(13), 2367–2376 (2006).
   PubMed Web of Science ®Google Scholar
• Pokorn M, Kopac S, Neubauer D, Cizman M. Economic evaluation of Haemophilus influenzae type b vaccination in Slovenia. Vaccine19(25–26), 3600–3605 (2001).
   PubMed Web of Science ®Google Scholar
• Harris A, Hendrie D, Bower C et al. The burden of Haemophilus influenzae type b disease in Australia and an economic appraisal of the vaccine PRP-OMP. Med. J. Aust.160(8), 483–488 (1994).
   PubMed Web of Science ®Google Scholar
• Livartowski A, Boucher J, Detournay B, Reinert P. Cost–effectiveness evaluation of vaccination against Haemophilus influenzae invasive diseases in France. Vaccine14(6), 495–500 (1996).
   PubMed Web of Science ®Google Scholar
• McIntyre P, Hall J, Leeder S. An economic analysis of alternatives for childhood immunisation against Haemophilus influenzae type b disease. Aust. J. Public Health18(4), 394–400 (1994).
   PubMedGoogle Scholar
• Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Boston: Harvard School of Public Health, MA, USA (1996).
   Google Scholar
• Trollfors B. Cost–benefit analysis of general vaccination against Haemophilus influenzae type b in Sweden. Scand.J. Infect. Dis.26(5), 611–614 (1994).
   PubMed Web of Science ®Google Scholar
• Walker D, Fox-Rushby J. Economic evaluation of parasitic diseases: a critique of the internal and external validity of published studies. Trop. Med. Int. Health5(4), 237–249 (2000).
   PubMed Web of Science ®Google Scholar
• Walker D, Fox-Rushby JA. Economic evaluation of communicable disease interventions in developing countries: a critical review of the published literature. Health Econ.9(8), 681–698 (2000).
   PubMed Web of Science ®Google Scholar
• Jefferson T, Demicheli V, Vale L. Quality of systematic reviews of economic evaluations in health care. JAMA287(21), 2809–2812 (2002).
   PubMed Web of Science ®Google Scholar
• Anderson R. Systematic reviews of economic evaluations: utility or futility? Health Econ. DOI: 10.1002/hec.1486 (2009) (Epub ahead of print).
   Google Scholar
• Murphy KM, Topel, RH. The value of health and longevity. J. Polit. Econ.114(5), 871–904 (2006).
   Web of Science ®Google Scholar
• Garpenholt O, Silfverdal SA, Levin LA. Economic evaluation of general childhood vaccination against Haemophilus influenzae type b in Sweden. Scand. J. Infect. Dis.30(1), 5–10 (1998).
   PubMed Web of Science ®Google Scholar